Logos Global Management LP Larimar Therapeutics, Inc. Transaction History

Logos Global Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$8.0 - $15.2 $1.84 Million - $3.5 Million	-230,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$14.61 - $22.19 $7.09 Million - $10.8 Million	-485,000 Reduced 67.83%	230,000 $3.36 Million
Q4 2020 Feb 16, 2021	BUY	$14.28 - $25.06 $5.5 Million - $9.65 Million	385,000 Added 116.67%	715,000 $15.3 Million
Q3 2020 Nov 16, 2020	BUY	$10.5 - $17.6 $2.86 Million - $4.8 Million	272,525 Added 474.16%	330,000 $5.01 Million
Q2 2020 Aug 14, 2020	BUY	$0.72 - $16.76 $41,382 - $963,281	57,475 New	57,475 $739,000

114

60.9M

1.37M

124K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $314M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.